These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7995277)

  • 1. Therapeutic potential of potassium channel activators in coronary heart disease.
    Haeusler G; Lues I
    Eur Heart J; 1994 Aug; 15 Suppl C():82-8. PubMed ID: 7995277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicorandil: a potassium channel opening drug for treatment of ischemic heart disease.
    Goldschmidt M; Landzberg BR; Frishman WH
    J Clin Pharmacol; 1996 Jul; 36(7):559-72. PubMed ID: 8844437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoplasmic calcium and the relaxation of canine coronary arterial smooth muscle produced by cromakalim, pinacidil and nicorandil.
    Yanagisawa T; Teshigawara T; Taira N
    Br J Pharmacol; 1990 Sep; 101(1):157-65. PubMed ID: 2149290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-angina activity of potassium-channel activators].
    Chiariello M; Duilio C; Ambrosio G
    Cardiologia; 1993 Dec; 38(12 Suppl 1):459-63. PubMed ID: 8020048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-ischaemic actions of potassium channel openers in experimental myocardial ischaemia/reperfusion injury in dogs.
    Auchampach JA; Gross GJ
    Eur Heart J; 1993 Jul; 14 Suppl B():10-5. PubMed ID: 8370365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
    Nielsen-Kudsk JE
    Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasorelaxant mechanism of KRN2391 and nicorandil in porcine coronary arteries of different sizes.
    Miwa A; Kaneta S; Motoki K; Jinno Y; Kasai H; Okada Y; Fukushima H; Ogawa N
    Br J Pharmacol; 1993 Jul; 109(3):632-6. PubMed ID: 8358563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicorandil: differential contribution of K+ channel opening and guanylate cyclase stimulation to its vasorelaxant effects on various endothelin-1-contracted arterial preparations. Comparison to aprikalim (RP 52891) and nitroglycerin.
    Borg C; Mondot S; Mestre M; Cavero I
    J Pharmacol Exp Ther; 1991 Nov; 259(2):526-34. PubMed ID: 1682478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral vascular smooth muscle potassium channels and their possible role in the management of vasospasm.
    Zhang H; Cook D
    Pharmacol Toxicol; 1994 Dec; 75(6):327-36. PubMed ID: 7899253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
    Satoh K
    Nihon Rinsho; 1993 May; 51(5):1293-8. PubMed ID: 8331797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potassium channel activators in vasospastic angina.
    Lablanche JM; Bauters C; McFadden EP; Quandalle P; Bertrand ME
    Eur Heart J; 1993 Jul; 14 Suppl B():22-4. PubMed ID: 8370368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil.
    Longman SD; Clapham JC; Wilson C; Hamilton TC
    J Cardiovasc Pharmacol; 1988; 12(5):535-42. PubMed ID: 2468052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of relaxation and repolarization mechanisms of nicorandil in rat mesenteric artery.
    Fujiwara T; Angus JA
    Br J Pharmacol; 1996 Dec; 119(8):1549-56. PubMed ID: 8982500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KATP-channel-induced vasodilation is modulated by the Na,K-pump activity in rabbit coronary small arteries.
    Glavind-Kristensen M; Matchkov V; Hansen VB; Forman A; Nilsson H; Aalkjaer C
    Br J Pharmacol; 2004 Dec; 143(7):872-80. PubMed ID: 15504751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels.
    Akai K; Wang Y; Sato K; Sekiguchi N; Sugimura A; Kumagai T; Komaru T; Kanatsuka H; Shirato K
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):541-7. PubMed ID: 8569213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relaxation of human coronary artery and arteria mammaria by K(+)-channel openers.
    Bossaller C; Auch-Schwelk W; Graf K; Gräfe M; Catadelgirmen G; Ennker J; Fleck E
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S13-6. PubMed ID: 1282170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Potassium channel activators. Perspectives in the treatment of arterial hypertension].
    Giudicelli JF; Richer C; Berdeaux A
    Presse Med; 1991 Jan; 20(2):75-81. PubMed ID: 1825708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potassium channel openers: pharmacological and clinical aspects.
    Quast U
    Fundam Clin Pharmacol; 1992; 6(7):279-93. PubMed ID: 1490649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system.
    Cavero I; Pratz J; Mondot S
    Z Kardiol; 1991; 80 Suppl 7():35-41. PubMed ID: 1838848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular acidification and ADP enhance nicorandil induction of ATP sensitive potassium channel current in cardiomyocytes.
    Jahangir A; Terzic A; Kurachi Y
    Cardiovasc Res; 1994 Jun; 28(6):831-5. PubMed ID: 7923287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.